Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells

International Journal of Molecular Medicine

Volumn 26, Issue 5, 2010, Pages 713-721

  Berezowska, Sabina ^a,e   Diermeier Daucher, Simone ^b   Brockhoff, Gero ^b   Busch, Raymonde ^c   Duyster, Justus ^a   Grosu, Anca Ligia ^d,f   Schlegel, Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Epidermal growth factor receptor; Glioblastoma; HER2 neu; Targeted therapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; PURINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TYRPHOSTINS;

EID: 77957867584     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000518     Document Type: Article

References (52)

1. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
2. Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489, 2005.
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652, 2002. (Pubitemid 34815868)
5. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64, 2002.
6. Weinstein IB and Joe A: Oncogene addiction. Cancer Res 68: 3077-3080, 2008.
7. Pillay V, Allaf L, Wilding AL, et al: The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11: 448-458, 2009.
8. Yarden Y and Sliwkowski MX: Untangling the erbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
9. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007. (Pubitemid 47339290)
10. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
11. Mineo JF, Bordron A, Baroncini M, et al: Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85: 281-287, 2007.
12. Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H and Hofler H: Expression of neu/c-ErbB-2 in human brain tumors. Hum Pathol 25: 772-780, 1994. (Pubitemid 2119175)
13. Haynik DM, Roma AA and Prayson RA: HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 15: 56-58, 2007.
14. Engelhard HH, Wolters M and Criswell PS: Analysis of c-erbB2 protein content of human glioma cells and tumor tissue. J Neurooncol 23: 31-40, 1995.
15. Torp SH, Gulati S, Johannessen E and Dalen A: Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res 26: 353-359, 2007.
16. Schlegel J, Stumm G, Brandle K, et al: Amplification and differential expression of members of the ErbB-gene family in human glioblastoma. J Neurooncol 22: 201-207, 1994.
17. Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187, 2005. (Pubitemid 41058349)
18. Ziegler DS, Kung AL and Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26: 493-500, 2008.
19. Brown PD, Krishnan S, Sarkaria JN, et al: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609, 2008.
20. Contessa JN, Hampton J, Lammering G, et al: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21: 4032-4041, 2002.
21. Nyati MK, Morgan MA, Feng FY and Lawrence TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6: 876-885, 2006.
22. Ishii N, Maier D, Merlo A, et al: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479, 1999.
23. Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF and Carrel S: Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol 53: 21-28, 1981. (Pubitemid 11178990)
24. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
25. Traxler P, Allegrini PR, Brandt R, et al: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64: 4931-4941, 2004.
26. Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8- phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248, 1994.
27. Pang L, Sawada T, Decker SJ and Saltiel AR: Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270: 13585-13588, 1995.
28. Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689, 1995.
29. Hall EJ: Cell survival curves. In: Radiobiology for the Radiologist. J.B. Lippincott Company, Philadelphia, 1994.
30. Dahle J, Kakar M, Steen HB and Kaalhus O: Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing. Cytometry A 60: 182-188, 2004.
31. Gulliford TJ, Huang GC, Ouyang X and Epstein RJ: Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2. Oncogene 15: 2219-2223, 1997. (Pubitemid 27493911)
32. Failly M, Korur S, Egler V, et al: Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 6: 773-781, 2007.
33. Gusterson BA and Hunter KD: Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol 10: 522-527, 2009.
34. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000.
35. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
36. Campiglio M, Locatelli A, Olgiati C, et al: Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198: 259-268, 2004.
37. Johnson DH and Arteaga CL: Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? J Clin Oncol 21: 2227-2229, 2003.
38. Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA and Shackney SE: HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 94: 1144-1153, 2006.
39. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF and Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001. (Pubitemid 34013905)
40. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001. (Pubitemid 32946513)
41. Brockhoff G, Heckel B, Schmidt-Bruecken E, et al: Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 40: 488-507, 2007.
42. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd and Thor AD: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160, 2005.
43. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23: 5007-5018, 2005.
44. Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933, 2004.
45. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005. (Pubitemid 41417939)
46. Riesterer O, Milas L and Ang KK: Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 25: 4075-4083, 2007.
47. Nakamura JL, Karlsson A, Arvold ND, et al: PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71: 215-222, 2005. (Pubitemid 40372948)
48. Riesterer O, Tenzer A, Zingg D, et al: Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy? Int J Radiat Oncol Biol Phys 58: 361-368, 2004.
49. Chakravarti A, Berkey B, Robins HI, et al: An update of phase II results from RTOG 0211: A phase I/II study of gefitinib + radiation for newly-diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 66: S83-S84, 2006.
50. Nyati MK, Maheshwari D, Hanasoge S, et al: Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10: 691-700, 2004.
51. De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567, 2008.
52. Potapova O, Laird AD, Nannini MA, et al: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5: 1280-1289, 2006. (Pubitemid 43881321)